CTI BioPharma Grants Inducements to Bolster Nasdaq Listing – March 21, 2023

CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company dedicated to the development and commercialization of groundbreaking treatments for blood-related cancers, proudly announced the granting of equity awards to four new employees as an incentive to join the company.

These equity awards, approved by an authorized subcommittee of the Compensation Committee of the Board of Directors on March 20, 2023, were made outside of the Amended and Restated 2017 Equity Incentive Plan, but in accordance with Nasdaq Listing Rule 5635(c)(4).

CTI BioPharma has granted its employees the opportunity to purchase 124,000 shares of its common stock, with the exercise price for each option equalling the closing price of the stock on the employee’s grant date.

Each option will vest in four installments, on each anniversary of the grant date, as long as the employee remains employed with CTI BioPharma. This generous offer extends over a ten-year period, providing employees with ample time to act on it.

About CTI BioPharma Corp.

CTI BioPharma is revolutionizing the way blood-related cancers are treated with their FDA-approved product, VONJO® (pacritinib). This JAK2, ACVR1, and IRAK1 inhibitor has been proven to offer a unique benefit to patients with intermediate- or high-risk primary or secondary myelofibrosis with a platelet count below 50 × 109/L, as it spares JAK1 activity.

As a post-marketing requirement, the company is currently conducting the Phase 3 PACIFICA study of VONJO to further verify its efficacy in patients with myelofibrosis and severe thrombocytopenia. With CTI BioPharma’s innovative approach, patients will have access to more effective treatments for their blood-related cancers.

Leave a Comment